Recent Advances in Anticancer Strategies, 3rd Edition

Dear Colleagues,

The topic "Recent Advances in Anticancer Strategies, 3rd Edition" aims to provide an overview of the latest developments in the field of cancer treatment. Cancer remains one of the leading causes of death worldwide, and researchers have been working to develop more effective and targeted treatments to improve outcomes for patients. The existing cancer therapies may cause severe side effects and tumors can develop drug resistance, leading to an increase in cancer mortality worldwide. Hence, there is a pressing need to develop and discover novel therapeutic strategies that can offer more effective and less-toxic treatment options for cancer patients. Novel anticancer approaches are being developed which can selectively identify and eliminate cancerous cells while minimizing harm to healthy tissues, unlike traditional therapies.

For this Topic, we welcome original articles and comprehensive reviews that showcase the latest advances in novel anticancer strategies with reduced toxicity and improved therapeutic indices. These articles can suggest potential prospects for optimizing cancer therapies with significant clinical value in the near future. We encourage submissions that focus on the development and validation of various anticancer approaches, including antibody-/ligand-/receptor-based targeting, controlled drug delivery, gene therapy, gene delivery, CAR-modified immune cell therapy, radionuclide–antibody conjugates, targeted anticancer prodrugs and conjugates (such as photoactivatable caged prodrugs, ADEPT, ADAPT, and ADCs), magnetic- and ultrasound-mediated drug targeting, and cancer stem cell therapy, as well as strategies that explore the targeting of signaling cascades, tumor angiogenesis, and immune suppressor cells (MDSC, TAM, CAF, TAN, etc.) in the tumor microenvironment.

Overall, this Topic aims at providing recent advances in anticancer strategies, highlighting the potential impact of these new approaches on cancer treatment and patient outcomes. We eagerly anticipate your valuable contribution to this exciting topic.

Dr. Hassan Bousbaa
Dr. Zhiwei Hu
Topic Editors